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BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW 
COMMENT 
GIVE AND TAKE-BACK: PHARMACEUTICAL 
MANUFACTURERS REQUIRED TO DISPOSE OF DRUGS 
AT LOCAL LEVEL 
ALLIE M. CRAVER * 
INTRODUCTION
6.5 million Americans use prescription drugs, such as pain            
relievers, stimulants, and tranquilizers, for purposes other than those 
prescribed.1 More than 50% of people ages 12 and older who abused 
prescription drugs received them from friends or family for free.2
Placed in the wrong hands, unconsumed and unwanted pharmaceuti-
cals expose vulnerable populations, including the elderly and       
children, to potential harm by means of ingestion.3 The United States 
Food and Drug Administration (FDA) suggest that medications be 
disposed by either trashing or flushing. Medications that have been 
trashed, which is the predominant method, can still be reused if not 
properly mixed with an unpalatable substance. Likewise, flushing 
medications can lead to toxins in the water supply.4 By first noting 
                                                                                                                          
* Allie M. Craver, North Carolina Central University School of Law, J.D., expected 
2017; Virginia Commonwealth University, M.A. Art History, 2013; East Carolina 
University, B.A. Art History, University Honors, magna cum laude, 2011. 
1.  of Pharmacy, The AWARXE Prescription Drug Safety 
Program, http://www.awarerx.org (last visited Jun. 16, 2015). 
2. Id. 
3.Carolyn S. Ma et al, i-
cs Enforcement Divi-
sion, 73 Haw. J Med Pub. Health 28, 26-31 (2014). 
4.U.S. Food and Drug Admin., Disposal of Unused Medicines, FDA.GOV, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSa
fely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm. (last 
updated Sept. 16, 2015). 
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the Environmental Protection 
concerning pharmaceutical disposal standards, this comment will 
explore the current issue of manufacturer-sponsored drug take-back 
initiatives implemented by local governments in the United States. 
Furthermore, this comment will address the question of whether 
pharmaceutical manufacturers should reciprocally give and take-back 
prescription drugs within the state of North Carolina. 
FEDERAL AGENCIES AND LEGISLATIVE HISTORY
Two federal agencies, the EPA and the Drug Enforcement Agency 
(DEA), are responsible for promulgating and enforcing regulations 
regarding the disposal of medications. Since the EPA seeks to protect 
to pass regulations concerning environmentally hazardous substanc-
es, such as pharmaceuticals.5 Because water treatment facilities in the 
United States are not equipped with the technology to filter the active 
compounds within prescription drugs, a low concentration of various 
pharmaceuticals is present in our water.6 A recent United State     
Geological Survey found that 110 of the 139 streams tested in 30 
states possessed trace amounts of pharmaceuticals including antibiot-
ics, antidepressants, caffeine, steroids, hypertensive drugs, and repro-
ductive hormones, to name a few.7 With this in mind, the EPA main-
tains a specific interest in the passing of federal guidelines regarding 
drug disposal programs. Furthermore, the EPA favors pharmaceutical 
take-back programs over the environmentally damaging alternative 
of flushing pharmaceuticals.8
Management Standards for Hazardous Waste Pharmaceuticals Rule 
                                                                                                                          
5.U.S. Environmental Protection Agency, How to Dispose of Medicines Properly,
(2011), http://water.epa.gov/scitech/swguidance/ppcp/upload/ppcpflyer.pdf. 
6.See Judith M. Mathias, Untangling Pharmaceutical Waste Requirements, 28 OR 
Manager 5 (May 2012), http://www.ormanager.com/wp-
content/uploads/pdf/ORMVo128No5PharmWaste.pdf. 
7.Herbert T. Buxton & Dana W. Kolpin, Pharmaceuticals, Hormones, and Other 
Organic Wastewater Contaminants in U.S. Streams, U.S. Geologic Survey, 
http://toxics.usgs.gov/pubs/FS-027-02/index.html (last updated Aug. 4, 2015). 
8.U.S. Environmental Protection Agency, How to Dispose of Medicines Properly,
(2011), http://water.epa.gov?scitech?swguidance/ppcp/upload/ppcpflyer.pdf.
36 BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW   Vol. IX 
Register on September 25, 2015.9 Because the Proposed Rule im-
numerous requests to extend the comment period and a public webi-
nar was held on October 13, 2015, to address some of the major con-
cerns.10 As part of the webinar, EPA representatives highlighted six 
remaining issues for rulemaking including: (1) pharmaceuticals being 
flushed and sewered, and (2) the intersection of EPA & DEA        
regulations.11
As one of the key concerns acknowledged by EPA officials, the 
flushing and sewering of pharmaceuticals is banned under the      
Proposed Rule. The EPA projects that the ban will prevent more than 
6,400 tons of flushed and sewered pharmaceuticals from entering the 
 year.12 Under the cur-
rent Resource Conservation and Recovery Act (RCRA), the public 
law that provides the framework for the proper management of     
hazardous and nonhazardous solid waste, the regulations provide an 
exemption for all hazardous waste generated by households, such as 
pharmaceuticals, and as such are not subject to RCRA protocols.13
Although flushing is allowed by RCRA regulations, the Proposed 
Rule stipulates that as part of a joint effort, the DEA will similarly 
ban the flushing and sewering of pharmaceuticals.14 Since toxins in 
                                                                                                                          
9. Management Standards for Hazardous Waste Pharmaceuticals, 80 Fed. Reg. 
58,014 (proposed Sept. 25, 2015) (to be codified at 40 C.F.R. pts 261, 262, 266, 
268, and 273).
10.The comment period for this proposed rule closed on December 24, 2015. Man-
agement Standards for Hazardous Waste Pharmaceuticals, 80 Fed. Reg. 68,491 
(extension Nov. 5, 2015) (to be codified at 40 C.F.R. pts 261, 262, 266, 268, and 
273). 
11.U.S. Environmental Protection Agency, Hazardous Waste Pharmaceuticals 
Proposed Rule, (2015), http://www.epa.gov/sites/production/files/2015-
10/documents/hw_pharmaceuticals_proposed_rule_3.pdf. 
12.U.S. Environmental Protection Agency, Proposed Rule: Management Standards 
for Hazardous Waste Pharmaceuticals, (2015), 
http://www.epa.gov/hwgenerators/proposed-rule-management-standards-
hazardous-waste-pharmaceuticals#rule-summary. 
13.40 C.F.R. § 261.4(b)(1) (2016). 
14.With the proposed rule, the EPA and DEA would join other states with sewer 
bans for pharmaceuticals, including: Connecticut, Illinois, New Jersey, and    
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the water supply threaten humans, animals, and aquatic ecosystems, 
the Proposed Rule seeks to improve compliance and establish     
safeguards by dividing the regulations into sector-specific standards, 
which clarify the process of reverse distribution and streamline     
disposal methods used by healthcare facilities and pharmacies.15
Although there are over 60 proposed changes to the preexisting    
regulations, only the pharmaceuticals that are currently considered 
hazardous waste under RCRA will be covered.16
Another area of contention addressed during the webinar involves 
the convergence of EPA and DEA policies. As the other major     
federal agency involved in pharmaceutical regulation, the DEA has 
the power to implement strict guidelines concerning drug disposal, 
once a drug is identified as a controlled substance.17 As part of its 
initiative to promote proper drug disposal, the DEA formulated its 
own final ruling on the disposal of controlled substances and has 
sponsored the National Take Back Day, a biannual event held in the 
spring and fall.18 However, prior to 2010, the DEA lacked clear 
guidelines concerning drug disposal. 
When Congress passed the Secure and Responsible Drug Disposal 
Act of 2010, the legislation provided long-term care facilities, and 
ultimate users, individuals originally prescribed the medication, with 
additional methods for safe and responsible drug disposal.19 The law 
also permitted federal, state, tribal and local law enforcement to 
maintain collection receptacles at law enforcement buildings.20
Likewise, law enforcement was permitted to collaborate with private 
entities or community groups to sponsor mail-back initiatives and 
                                                                                                                          
Washington. Management Standards for Hazardous Waste Pharmaceuticals, 80 
Fed. Reg. at 58,014. 
15.
not limited to: hospitals, pharmacies, health clinics, surgical centers, long-term care 
facilities, physician offices, veterinary clinics and hospitals, drug compounding 
facilities, coroners and medical examiners. Id. 
16.For a definition of hazardous waste pharmaceuticals, see 40 C.F.R. § 261.3 
(2016). 
17.21 C.F.R §1317.01 (2014). 
18. Id. 
19.Secure and Responsible Drug Disposal Act of 2010, Pub. L. No. 111-273, 124 
Stat. 2858. 
20. Id. 
38 BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW   Vol. IX 
hold take-back events.21 Take-back events aim to educate participants 
about the potential for abuse of medications, while providing safe, 
convenient, and responsible means of disposing of prescription drugs.
Take-back events are typically short in duration and are commonly 
held at unregistered locations that are easily accessible to the pub-
lic.22 Despite expanding the ways ultimate users could dispose of 
pharmaceuticals, participation in these programs is not mandatory, 
nor could the DEA require an entity to establish or operate a disposal 
program. 
The following year, the issue of proper drug disposal was one of 
Prescription Drug Abuse Prevention Plan.23 The government plan 
proposed that Americans receive access to safe drug disposal meth-
ods that, in turn, would protect both their health and the                 
environment.24 As part of this initiative, in December 2012, the DEA 
proposed allowing drug manufacturers, distributors, reverse distribu-
tors, and retail pharmacies to establish voluntary collection           
receptacles without the presence of an authorized agent. This       
proposal was a departure from earlier federal guidelines requiring an 
authorized agent be present on-site.25
As this issue received more attention, the FDA updated its      
-retrievable standard of destruction 
non-retrievable standard would have mandated that a controlled    
substance be permanently altered, making it unavailable and         
unusable for any purpose.26 Furthermore, the 2013 proposal noted 
that simply mixing a substance with coffee grounds or flushing the 
                                                                                                                          
21. Id. 
22.See Office of National Drug Control Policy, Take-back events frequently are 
held at community centers. 
23.Office of National Drug Control Policy, Prescription Drug Abuse, The White 




26.U.S. Department of Justice: Office of Diversion Control, Disposal Act: General 
Public Fact Sheet, (Oct. 17, 2014), 
http://www.deadiversion.usdoj.gov/drug_disposal/fact_sheets/disposal_public.pdf. 
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substance would not render the substance non-retrievable. Therefore, 
the 2013 proposal advocated for chemical digestion or incineration of 
a controlled substance as the proper means of disposal. As noted by 
other scholars, this was the first time a federal agency specifically 
undermined the long-established, yet environmentally destructive, 
method of flushing, mixing, or trashing controlled substances.27
On October 9, 2014, components of the 2013 proposal, including 
the preference for mail-back or take-back programs, were             
Published Disposal of Controlled      
Substances Final Rule. In accordance with the Controlled Substances 
Act, the ruling expands those who are permitted to collect controlled 
substances through methods such as take-back events, mail-back 
programs, and collection receptacle locations.28 As stated in previous 
regulations, any DEA registrant, or federal, state, tribunal, or local 
law enforcement agency is authorized to collect medications from an 
ultimate user or other accepted entity. The final rule further expands 
the list of authorized collection registrants to include: manufacturers, 
distributors, reverse distributors, narcotic treatment programs, retail 
pharmacies, and medical centers with an on-site pharmacy.29
Considering the current collaboration between the EPA and DEA, as 
further regulations concerning proper drug disposal and voluntary 
collection receptacles should be expected. 
THE IMPORTANCE OF TAKE-BACK PROGRAMS
Prescription drug abuse is the fastest growing drug problem in the 
United States. In order to help stop the non-medical use of             
prescription drugs, the DEA has developed programs such as take-
back events and mail-back programs to facilitate the handling,     
monitoring, and proper disposal of pharmaceuticals. The efficacy of 
the DEA-sponsored National Take Back Days is unquestionable: as a 
                                                                                                                          
27. Disposal of Controlled Substances, 79 Fed. Reg. 53,520-01 (Sept. 9, 2014) (to 
be codified at 21 C.F.R. pts. 1300, 1301, 1304, 1305, 1307, and 1317). See further 
in Cook, supra note 34, at 14.
28. Id. 
29.21 C.F.R. § 1317.40 (2014). 
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result of nine events held over the span of four years, over 2,411 tons, 
or 4,823,251 pounds, were returned.30
Although access to these programs may be limited to particular 
highly-populated regions, the FDA and DEA suggests that if a     
take-back program is not available in an area and there are no        
thrown in the trash after following two essential steps. First, the drug 
should be removed from its original container and mixed with an 
31
Second, the mixture should be placed in a sealable bag or container 
to prevent leakage after it is thrown out. Although these trashing   
precautions may seem tedious, labels on certain pharmaceuticals  
direct that users dispose of the drug by flushing.32 For example, if a 
fentanyl patch, an adhesive patch that delivers a powerful pain medi-
cine, is not properly disposed of by flushing, minimal skin contact 
can cause severe breathing problems that can lead to death in chil-
dren, adults, and pets.33 With these issues in mind, establishing a na-
tional take-back system would help to prevent non-prescription  
holders from accessing dangerous medications, while also reducing 
the amount of toxic chemicals in our waters caused by the flushing of 
medications. 
While take-back and drug disposal programs benefit both          
consumers and the environment, the issue of who is responsible for 
funding divides the pharmaceutical industry. Recently passed       
legislation from Alameda County, California and King County, 
Washington requires pharmaceutical manufacturers to fund drug    
disposal programs. However, the major controversy now concerns 
which entity should be responsible for the costs of these widespread 
initiatives. 
                                                                                                                          
30.U.S. Drug Enforcement Administration, DEA and Partners Collect 309 Tons of 
Pills on Ninth Prescription Drug Take-Back Day, DEA (Nov. 4, 2014), 
http://www.dea.gov/divisions/hq/2014/hq110514.shtml. 
31.U.S. Food and Drug Admin., Disposal of Unused Medicines, FDA.GOV, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSa
fely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm. (last 
updated Jun. 4, 2015). 
32. Id. 
33. Id. 
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THE ALAMEDA COUNTY ORDINANCE
In December of 2012, Pharmaceutical Research and Manufacturers 
of America, the Biotechnology Industry Organization, and the      
Generic Pharmaceutical Association filed a lawsuit in the United 
States District Court for the Northern District of California          
challenging an Alameda County Ordinance as unconstitutional.34
Originally approved by county supervisors in July 2012, the Safe 
Drug Disposal Ordinance of Alameda County established a        
countrywide, manufacturer-sponsored drug disposal program applied 
to all manufacturers that make their drugs available in the county 
In Alameda County alone, pharmaceutical companies collect $950 
million a year in sales.35 Considering this influx of dispensed       
medications, the county spends $330,000 a year to operate approxi-
mately 30 medication drop-off sites where consumers can discard 
their pills.36 County officials who backed the ordinance claimed drug 
companies should bear the cost of disposing their products for the 
37 Yet, drug 
manufacturers estimated that the annual cost of complying with the 
ordinance would be $1.2 million a year 
estimate of $330,000.38 Officials for the county argued that the    
manufacturers could recoup their costs by raising prices in Alameda 
County by one cent for each $10 in sales.39 Given these differences in 
opinion, pharmaceutical trade groups filed suit in federal court,     
                                                                                                                          
34.Bryan Cook, Comment, H2Whoa?!: An Examination of the Presence of Phar-
, 35 J. Legal Med. 211, 16 (2014). 
35.Mark Lowery, Federal Court Upholds Groundbreaking Drug-Disposal Law, 
Modern Medicine Network (Jun. 16, 2015), 
http://drugtopics.modernmedicine.com/drug-topics/news/federal-court-upholds-
groundbreaking-drug-disposal-law?page=0,1. 
36.  Bob Egelko, 





39.Mark Lowery, Federal Court Upholds Groundbreaking Drug-Disposal Law, 
Modern Medicine Network (Jun. 16, 2015). 
42 BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW   Vol. IX 
alleging an unconstitutional burden on interstate commerce, in       
violation of the Commerce Clause.40
The pharmaceutical manufacturer trade groups claimed the         
ordinance was unconstitutional because i per se violation of 
on interstate commerce.41 More specifically, they argued that the  
ordinance was an illegal violation of interstate commerce since it 
placed local costs on out-of-state producers. The trade groups found 
further support from the California Healthcare Institute, who claimed 
that these take-back programs may lead to higher priced medications 
and that the financial burden was unfairly placed on a single      
stakeholder, the manufacturer, rather than spread amongst other 
stakeholders, such as local governments, hospitals, pharmacies, 
healthcare organizations, and patients.42
In Pharmaceutical Research and Manufacturers of America v. 
County of Alameda, the court granted summary judgment in favor of 
shown that the Ordinance serves a legitimate public health and safety 
interest, and that the relatively modest compliance costs producers 
will incur should they choose to sell their products in the county do 
not unduly burden interstate commerce.43 This decision was appealed 
to the U.S. Court of Appeals, where, in a 3-0 decision, the Ninth  
Circuit 
             
unreasonably burden interstate business since it applied to every 
manufacturer supplying in the area.44 The court further added, [t]he 
fact that the county could run a similar program does not nullify the 
                                                                                                                          
40.Pharmaceutical Res. & Manufacturers of Am. v. County of Alameda, 967 
F.Supp.2d 1339 (N.D. Cal. Aug. 28, 2013), , 768 F.3d 1037, (9d Cir.  2014). 
41.Id. at 1344. 
42.
Healthcare Inst, to Honorable Nathan A. Miley, Pres. Alameda County Board of 
Supervisors (July 9, 2012), http://calpsc.org/admin-document-upload/doc-
download/823-california-healthcare-institute-letter-of-opposition-7-9-12. See 
Cook, supra note 34, at 232-33. 
43.Pharm. Research & Mfrs. & Manufacturers of Am. v. Cnty. County of Alameda,
967 F.Supp.2d 1339, 1346 (N.D. Cal. 2013), , 768 F.3d 1037, (9d Cir.  2014). 
44.Pharm. Research & Mfrs. & Manufacturers of Am. v. Cnty. County of Alameda,
768 F.3d 1037 (9d Cir. Sept. 30, 2014).
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45
Because the pharmaceutical industry has the lobbying power to 
prevent similar manufacturer-sponsored drug disposal programs at 
was decisive in regards to future legislation.46 These judgments    
concerning local take-back ordinances may lead to significant action 
in both California and Washington state governments. Scholars have 
noted that, in 2013, the California legislature considered legislation 
modeled in part after the Alameda County ordinance. Likewise, the 
Washington legislature introduced a bill requiring manufacturers to 
establish a drug take-back program in 2011, which was reintroduced 
in 2012.47
localized take-back ordinances, nine state governments have         
introduced, but not yet passed, pharmaceutical take-back               
legislation.48 If federal courts are willing to uphold drug take-back 
programs, perhaps more state or local governments will be inclined 
to develop similar legislation. 
IMPLEMENTING LOCAL TAKE-BACK PROGRAMS IN NORTH CAROLINA
The EPA, FDA, and DEA highly recommend that individuals take 
their expired or unwanted pharmaceuticals to drug take-back pro-
grams and disposal sites and only trash drugs if there are no programs 
available in the area. Despite the fact that some states readily main-
tain take-back initiatives, these programs are commonly underfunded 
and are primarily available in larger cities.49
                                                                                                                          
45.Id. at 1045 (citing -Herkimer Solid Waste 
Mgmt. Auth., 550 U.S. 330, 346). 
46.Mark Lowery, Federal Court Upholds Groundbreaking Drug-Disposal Law, 
Modern Medicine Network (Jun. 16, 2015). 
47.Caroline Wick, Comment, Mandatory Drug Take-Back Programs: Will They 
Survive the Dormant Commerce Clause Challenge?, 27 Tul. Envtl. L.J. 371, 391 
(2014). 
48.Id. at 391. 
49.Id. at 375. 
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In North Carolina, the total number of retail prescription drugs 
filled at pharmacies during 2014 was 102,887,597.50 Considering the 
large quantity of prescription drugs dispensed within the state, there 
are only 193 locations, primarily local law enforcement agencies and 
police departments, which operate throughout the year as drug       
disposal sites.51 These locations are unevenly dispersed throughout 
their settings, could dissuade some consumers from taking action.52
Even though the biannual National Take Back Days raise awareness 
for the necessity of proper pharmaceutical disposal, they are too    
infrequent, and are too limited to make a significant impact in North 
Carolina.53
As part of the National Take Back Day held on September 27, 
2014, North Carolina had 74 groups of law enforcement participating 
at 119 collection sites, and a total weight of 10,154 pounds of     
pharmaceuticals collected.54
146 groups of law enforcement, 210 collection sites, and a total of 
21,872 pounds, North 
          
population.55 Based on the 2014 United States Census, North        
Carolina ranks in the top ten for highest state population, with an  
estimate of 9,943,964 people.56 During the same National Take Back 
Day, other heavily populated states maintained significantly higher 
numbers than North Carolina: they had more than 150 groups of law 
                                                                                                                          
50.The Henry J. Kaiser Family Foundation, Total Number of Retail Prescription 
Drugs Filled at Pharmacies, KFF (Jun. 1, 2015), http://kff.org/other/state-
indicator/total-retail-rx-drugs/?state=NC. 
51.N.C. Dept. of Ins., North Carolina Operation Medicine Drop, N.C. D.O.I. (last 
visited Feb. 13, 2016), https://apps.ncdoi.net/f?p=102:1:8854982067030::NO:::. 
52. Id. 
53. Id. 
54.Drug Enforcement Administration, Diversion Control Program: National Take 
Back Day, September 27, 2014, DEA (Sept. 27, 2014), 
http://www.dea.gov/divisions/hq/2014/hq110514.pdf. 
55. Id. 
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enforcement, more than 200 collection sites, and the majority had 
double the weight of pharmaceuticals collected.57 Going forward, 
supporters of drug disposal programs in North Carolina should not be 
concerned with its ranking or numbers in regards to the National 
Take Back Days. Adhering to their newly implemented rule, the 
DEA will not continue to sponsor nationwide take-back events in 
order to prevent competition with local efforts conducted in          
accordance with the new regulations.58 Realizing the impressive    
national total of 617,150 pounds, or 309 tons, from this past National 
Take Back Day and the call to action for which it creates, the      
question remains as to how successful localized efforts will be    
compared to those sponsored by the DEA. 
ide 
event sponsored by Attorney General Roy Cooper, the State Bureau 
of Investigation, local sheriffs and police, the North Carolina        
Department of Insurance, and the DEA, approximately 61 million 
doses of pharmaceuticals were properly disposed of in a span of five 
years.59 During the week-long event held in March 2014, more than 
eight million doses of old prescription drugs and over-the-counter 
drugs were collected. However, as the collection results were tallied, 
it became apparent that the larger county police departments were 
responsible for the majority of the collections.60 Similarly, statewide 
efforts should be made to establish permanent and diversified        
location sites, which in turn would prompt higher totals throughout 
the year. 
However, initiating a local take-back program is not an easy task. 
One of the major obstacles concerning take-back initiatives is the 
amount of public education required to foster a successful event. 
Some earlier take-back events permitted only controlled substance 
disposal because the FDA and DEA maintained strict regulations on 
which drugs fell under the classification as well as those which could 
                                                                                                                          
57.Drug En supra note 50. 
58. supra note 30. 
59.N.C. Dept. of Justice, More Than 8 Million Pills Turned in During Operation 
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be mixed.61 Because of the costs of separating medications, today, 
most take-back events allow for the comingling of controlled and 
non-controlled substances, as seen in Operation Medicine Drop.62
Likewise, this comingling ensures the proper disposal of all        
pharmaceuticals in a non-retrievable fashion. However, sponsors of 
these events may specify that only controlled substances will be    
accepted and could offer a separate receptacle designated for        
non-controlled substances. Regardless of the classification, all of the 
collected pharmaceuticals should be securely stored or transferred 
until rendered non-retrievable. Becoming non-retrievable by         
incineration, the collected drugs will be incapable of being re-sold,       
repackaged, or re-dispensed.63
Another issue concerning the take-back event is safety. The DEA 
believes that it is imperative to establish active law enforcement   
participation for the safety of event participants and the community.64
Because of the low physical security at such locations, the presence 
of law enforcement will help deter theft and prevent the diversion of 
controlled substances. Since there is not a national requirement for 
pharmaceuticals to be in their original packaging, nor is there a     
requirement that anyone provide personal information about      
themselves, their prescription, or their physician, some organizations 
are concerned that these events may incite greater crime.65
Although establishing a take-back event could be seen as an        
arduous task for a local organization, some alternative groups within 
North Carolina could help expand the effort. As noted by other 
scholars, the Veterans Health Administration (VA) medical system is 
the largest healthcare network in the United States and should be   
utilized in the expansion of local and statewide pharmaceutical take-
back programs.66
locations, its integrated medical system, and its on-site pharmacies 
                                                                                                                          
61. supra note 50. 
62. supra note 55. 
63. supra note 30. 
64. Id. 
65. Id. 
66.Tamika Brown, Implications for a Drug Take Back Program in the Veterans 
Affairs Healthcare System (2014) (M.A. of Environmental Assessment thesis, 
North Carolina State University). 
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reaching 8.76 million veterans annually, the VA has the resources, 
facilities, and patrons to become a major benefactor.67 Likewise,   
medical facilities are now able to purchase containers for the disposal 
of pharmaceuticals. 
Yet, some pharmacies are wary of forming partnerships with local 
take-back programs. According to the American Pharmacist          
Association, there are two major concerns: cost and liability.68 Some 
American companies offering this disposal service price a set of 50 
envelopes at $249 plus shipping and handling along with the         
additional charge of state tax.69 Furthermore, pharmacies would incur 
the expenses of providing permanent receptacles, fees for            
transportation and disposal, as well as outreach and publicity         
materials. With respect to liability, the DEA ruling mandates that an 
employee be present at the receptacle site; therefore, the question of 
who would be liable if the receptacles are tampered with or stolen 
remains unanswered.70
Quite possibly, the easiest solution is to follow the examples set by 
Alameda County, California and King County, Washington. Having 
noted the successful ordinances in both locations, North Carolina 
state and local governments should devise a similar approach because 
drug manufacturers have the finances, accessibility, and manpower to 
assist disposal programs. 
Located in North Carolina, The Research Triangle Park (RTP) is 
the largest research park in the country and is home to more than 200 
companies in the fields of micro-electronics, telecommunications, 
biotechnology, chemicals, environmental sciences, and              
pharmaceuticals.71 These RTP industries invest more than $296     
million in research and development in North Carolina, which is 
double the average investment for other national innovation clusters, 
and could easily help fund, publicize, and supervise a drug disposal 
                                                                                                                          
67. Id. 
68.Desiree Hodges, Prescription Take-Back Programs 23 (March 26, 2015) 
(PharmD. Candidate 2015 thesis, New Mexico Pharmacists Association). 
69. Id. 
70. Id. 
71.The Research Triangle Park, About Us, RTP (last visited Jun. 16, 2015), 
http://www.rtp.org/about-us/. 
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program within the state.72 If RTP manufacturers challenge whether 
an ordinance could be successful long term, proponents of take-back 
programs should cite the British Columbia Waste Management Act of 
1997.73 The act fostered the Post-Consumer Pharmaceutical        
Stewardship Association, a group that placed collection bins in 
pharmacies throughout the province, and facilitated the transfer and 
incineration of collected pharmaceuticals.74 The association, fully 
funded by pharmaceutical manufacturers and brand owners, helped 
collect 4,500 kilograms of medications from 75% of pharmacies in 
the area in 2000.75 Only ten years later, 60,500 kilograms were     
collected from 96% of the area pharmacies. According to researchers, 
if the same amount of Americans participated in a similar            
manufacturer-sponsored disposal program, more than 5.4 million 
kilograms, or 12 million pounds, of pharmaceuticals would be      
collected.76 Advocates of the drug take-back events should extend 
their North Carolina campaign to RTP since the site offers plentiful 
resources as well as a diverse field of related industries. In North 
Carolina, a manufacturer-sponsored drug take-back ordinance should 
be implemented to ensure that both urban and rural residents have 
access to facilities that can properly and safely dispose of unused 
pharmaceuticals. 
CONCLUSION
Drug take-back initiatives have the potential to modernize the    
system of pharmaceutical distribution. Medical professionals could 
use the data collected from unused and overprescribed medications to 
streamline the healthcare system, which would have a positive impact 
on the environment and the overall health of society. If              
pharmaceuticals were prescribed as based on these findings, it is less 
likely they would be improperly disposed or consumed.                 
Coincidentally, the Director of the Office of National Drug Control 
Policy projects a similar future of pharmaceutical disposal that will 
                                                                                                                          
72. Id. 
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-nature to most Americans, in much the same way as 
77
 recently Proposed Rule, pharmaceutical 
waste poses a threat to the environment, to consumers, and to        
corporations responsible for their manufacture. Given the decisions 
in California and Washington requiring drug manufacturers to     
sponsor local take-back programs, many other counties and districts 
in North Carolina, and throughout the United States, could adopt   
similar ordinances. In regards to the current state of pharmaceutical 
development, these impending costs on pharmaceutical               
manufacturers may lead to raised prices and stricter guidelines      
regarding drug manufacture and distribution. However, upon         
realizing the health benefits of drug disposal programs, it is all a   
matter of give and take. 
                                                                                                                          
77.See Wick, supra note 47, at 391. 
